Reports Q2 revenue $3.16B, consensus $3.01B. “Regeneron delivered strong financial results in the second quarter of 2023 through increasingly diversified revenue streams, and we remain well-positioned for long-term growth,” said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. “In the past months, we have continued to advance our pipeline, in particular aflibercept 8 mg which we are progressing towards a potential FDA decision in the third quarter and for which we shared unprecedented two-year results in the pivotal PHOTON trial demonstrating durable vision gains at extended dosing intervals in patients with diabetic macular edema.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron Reports Second Quarter 2023 Financial and Operating Results
- Notable companies reporting before tomorrow’s open
- Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
- REGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Regeneron presents aflibercept 8 mg two-year results from pivotal PHOTON trial